Sub-lobectomy vs Lobectomy in IIA-IIIB NSCLC After Neoadjuvant IO+Chemo

Inclusion criteria

• Voluntarily participate in the research and sign an informed consent form;
• Age ≥ 18 years old,<75 years old, both male and female;
• The physical fitness status score of the Eastern Cooperative Oncology Group (ECOG) in the United States is 0 or 1;
• Expected survival period ≥ 12 months;
• Peripheral non-small cell lung cancer (NSCLC) confirmed by histology/pathology, with TNM staging of IIA~IIIB before neoadjuvant therapy (IASLC 9th edition), without known EGFR mutations/ALK rearrangements;
• No solid lesions involving different lung lobes;
• No history of ipsilateral open chest surgery;
• Prior to enrollment, the patient has received 2-4 cycles of neoadjuvant therapy, which includes PD-1/PD-L1 inhibitors and platinum based dual drug chemotherapy;
• Having sufficient organ function
• According to the researcher's assessment, the cardiovascular and pulmonary function meets the criteria for accepting surgery; The forced expiratory volume in the first second (FEV1) of the lung function test should be at least 1.5 L or the diffusion volume of carbon monoxide (DLCO) in the lungs should be at least 40%; The researchers determined that there was no other impact on the heart and lung function impairment during the surgery;
• Based on preoperative CT diagnosis, the distance between the tumor and the bronchial opening is greater than 2cm;
• After evaluation by the evaluation committee, the lesion can be treated with sub lobe R0 resection after neoadjuvant therapy.

Exclusion criteria

• Expected intolerance to lobectomy;
• Received chest radiation therapy before starting surgical treatment;
• Have undergone allogeneic tissue/solid organ transplantation;
• Diagnosed with autoimmune disease or undergoing long-term systemic steroid therapy (prednisone or equivalent dosage exceeding 10 mg/day) or any other form of immunosuppressive therapy within 3 months prior to surgery;
• There is a history of interstitial lung disease (non infectious) that requires steroid treatment or currently has interstitial lung disease that requires steroid treatment;
• Viral infectious disease in screening period:

Positive for human immunodeficiency virus (HIV) serum reaction; Active hepatitis B: Hepatitis B virus surface antigen (HBsAg) positive and HBV-DNA quantitative detection>500 IU/mL or>2000 copies/mL; Active hepatitis C: Hepatitis C (HCV) antibody positive and HCV-RNA quantitative detection above the upper limit of normal;

• Hypertension participants with poor drug treatment control are defined as systolic blood pressure>150 mmHg or diastolic blood pressure>90 mmHg (it is allowed to adjust the treatment of hypertension drugs before the start of the study, but the average value of the latest three consecutive blood pressure records before enrollment in the study should be ≤ 150/90 mmHg) (each measurement should be at least 2 minutes apart);
• During screening, there are still active infections that require intravenous anti infective treatment;
• Other malignant tumors, excluding cured skin basal cell cancer, cervical or breast cancer in situ, superficial bladder cancer cancer, localized prostate cancer, etc., within 3 years before signing the informed consent; Participants with low-risk early prostate cancer (T1-T2a stage, Gleason score ≤ 6, PSA<10 ng/mL) who have received curative treatment or are under active monitoring with stable condition, regardless of whether they have received treatment, are allowed to be enrolled;
• There are situations that may interfere with the interpretation of research results or may affect participants' ability to complete the entire research process, or based on the judgment of the treatment researcher, participation in the research is not in the best interests of the participants;
• Pregnancy, lactation, or planned pregnancy; Positive blood pregnancy test within 7 days prior to the first study treatment;
• Participants have poor compliance and are unwilling or unable to follow the research protocol.